Search Results

Broad Action Against Multidrug Resistant Pathogens Leads to Name Change from Novoclem Therapeutics to Vast Therapeutics.

The QIDP designation, granted for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, will make BIOC51 eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act.

The patent lists Mark Schoenfisch and Yuan Lu as inventors and is assigned to the University of North Carolina at Chapel Hill.

The in vitro work, carried out by researchers at Southern Research Institute showed that BIOC51 was bactericidal against the following pathogens, several of which have been categorized as a significant public health threat according to the CDC.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles

OraSure Technologies, Inc. announced today the appointment Nancy J. Gagliano, M.D. and Anne C. Whitaker to the Company’s Board of Directors, effective November 8, 2021.